Literature DB >> 14530725

Lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: therapeutic utility and implications of nodal microanatomy and molecular staging for improving the accuracy of detection of nodal micrometastases.

Donald L Morton1, Dave S B Hoon, Alistair J Cochran, Roderick R Turner, Richard Essner, Hiroya Takeuchi, Leslie A Wanek, Edwin Glass, Leland J Foshag, Eddy C Hsueh, Anton J Bilchik, David Elashoff, Robert Elashoff.   

Abstract

OBJECTIVE: Lymphatic mapping and sentinel lymphadenectomy (LM/SL) have been applied to virtually all solid neoplasms since our original description of LM/SL for melanoma. Our objectives were to determine the diagnostic and therapeutic utility of LM/SL, investigate carbon dye for mapping the microanatomy of lymphatic flow within the sentinel node (SN), and determine the prognostic accuracy of molecular assessment of the SN.
METHODS: Since 1985, 1599 patients with AJCC Stage I/II melanoma have been treated by LM/SL at our institution and 4590 have been treated by wide excision (WE) without nodal staging. We examined the incidence of clinical nodal recurrence after WE alone, the incidence of subclinical nodal metastases found by LM/SL, and the incidence of nodal recurrence in basins with histopathology-negative SNs.
RESULTS: In 1514 LM/SL patients with a primary of known Breslow thickness, the incidence of metastasis in nodes claimed to be sentinel was 7.3%, 19.7%, 33.2%, and 39.7% for primary lesions </=1.0, 1.01-2.0, 2.01-4.0, and >4.0 mm, respectively. In 3652 WE-only patients, the corresponding rates of nodal recurrence were 12.0%, 32.0%, 34.4%, and 30.1%. Thus, LM/SL detected only 60% of expected nodal metastases from primary melanomas <2.01 mm. Forty of 1599 (3.1%) patients developed recurrence in basins with immunohistochemistry (IH)-negative SNs. To determine whether nonrandom intranodal distribution of tumor cells could explain missed SN metastases, we coinjected carbon particles and blue dye during LM/SL in 166 patients: 25 (16%) patients had nodal metastases, all of which were found only in nodal subsectors containing carbon particles. When paraffin-embedded SNs from a subset of 162 IH-negative patients were re-examined by quantitative multimarker reverse-transcriptase polymerase chain reaction (qRT) assay, 49 (30%) gave positive signals. These patients had a significantly higher risk of disease recurrence and death than did patients whose IH and qRT results were negative (p < 0.0001). Comparison of 287 prognostically matched pairs of patients who underwent immediate (after LM/SL) versus delayed (after observation) dissection of nodal metastases revealed 5-, 10-, and 15-year survival rates of 73%, 69%, and 69% versus 51%, 37%, and 32%, respectively (P < or = 0.001).
CONCLUSIONS: SN assessment based on intranodal compartmentalization of lymphatic flow (carbon dye mapping) should increase the accuracy of IH and, in combination with multimarker qRT assessment, will allow confident identification of most patients for whom surgery alone is curative. Our data suggest a significant therapeutic benefit for immediate dissection based on identification of a tumor-involved SN.

Entities:  

Mesh:

Year:  2003        PMID: 14530725      PMCID: PMC1360112          DOI: 10.1097/01.sla.0000086543.45557.cb

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  28 in total

1.  Efficacy of lymphatic mapping, sentinel lymphadenectomy, and selective complete lymph node dissection as a therapeutic procedure for early-stage melanoma.

Authors:  R Essner; A Conforti; M C Kelley; L Wanek; S Stern; E Glass; D L Morton
Journal:  Ann Surg Oncol       Date:  1999 Jul-Aug       Impact factor: 5.344

2.  Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients.

Authors:  P J Bostick; D L Morton; R R Turner; K T Huynh; H J Wang; R Elashoff; R Essner; D S Hoon
Journal:  J Clin Oncol       Date:  1999-10       Impact factor: 44.544

3.  Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes.

Authors:  J F Thompson; W H McCarthy; C M Bosch; C J O'Brien; M J Quinn; S Paramaesvaran; K Crotty; S W McCarthy; R F Uren; R Howman-Giles
Journal:  Melanoma Res       Date:  1995-08       Impact factor: 3.599

4.  Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine.

Authors:  E C Hsueh; R K Gupta; K Qi; D L Morton
Journal:  J Clin Oncol       Date:  1998-09       Impact factor: 44.544

5.  Increased incidence of second primary melanoma in patients with a previous cutaneous melanoma.

Authors:  L A DiFronzo; L A Wanek; R Elashoff; D L Morton
Journal:  Ann Surg Oncol       Date:  1999 Oct-Nov       Impact factor: 5.344

6.  Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group.

Authors:  D L Morton; J F Thompson; R Essner; R Elashoff; S L Stern; O E Nieweg; D F Roses; C P Karakousis; N Mozzillo; D Reintgen; H J Wang; E C Glass; A J Cochran
Journal:  Ann Surg       Date:  1999-10       Impact factor: 12.969

7.  Carbon dye as an adjunct to isosulfan blue dye for sentinel lymph node dissection.

Authors:  A Lucci; R R Turner; D L Morton
Journal:  Surgery       Date:  1999-07       Impact factor: 3.982

8.  Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes. Analysis of prognostic factors in 1134 patients from the John Wayne Cancer Clinic.

Authors:  D L Morton; L Wanek; J A Nizze; R M Elashoff; J H Wong
Journal:  Ann Surg       Date:  1991-10       Impact factor: 12.969

9.  Universal application of intraoperative lymphatic mapping and sentinel lymphadenectomy in solid neoplasms.

Authors:  A J Bilchik; A Giuliano; R Essner; P Bostick; P Kelemen; L J Foshag; S Sostrin; R R Turner; D L Morton
Journal:  Cancer J Sci Am       Date:  1998 Nov-Dec

10.  Antibody responses to melanoma/melanocyte autoantigens in melanoma patients.

Authors:  S K Huang; T Okamoto; D L Morton; D S Hoon
Journal:  J Invest Dermatol       Date:  1998-10       Impact factor: 8.551

View more
  56 in total

Review 1.  Sentinel node biopsy in melanoma: technical considerations of the procedure as performed at the John Wayne Cancer Institute.

Authors:  Sanjay P Bagaria; Mark B Faries; Donald L Morton
Journal:  J Surg Oncol       Date:  2010-06-15       Impact factor: 3.454

Review 2.  Overview and update of the phase III Multicenter Selective Lymphadenectomy Trials (MSLT-I and MSLT-II) in melanoma.

Authors:  Donald L Morton
Journal:  Clin Exp Metastasis       Date:  2012-06-24       Impact factor: 5.150

3.  Epitrochlear sentinel lymph nodes in melanoma: interval or independent?

Authors:  Travis B Kidner; Jeong L Yoon; Mark B Faries; Donald L Morton
Journal:  Am Surg       Date:  2012-06       Impact factor: 0.688

4.  Sentinel node biopsy and selective lymph node clearance--impact on regional control and survival in breast cancer and melanoma.

Authors:  Omgo E Nieweg; Maartje C van Rijk; Renato A Valdés Olmos; Cornelis A Hoefnagel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-06       Impact factor: 9.236

5.  [Selective sentinel node biopsy in melanoma].

Authors:  Luis Cabañas Navarro
Journal:  Clin Transl Oncol       Date:  2005-05       Impact factor: 3.405

6.  Tumor-induced sentinel lymph node lymphangiogenesis and increased lymph flow precede melanoma metastasis.

Authors:  Maria I Harrell; Brian M Iritani; Alanna Ruddell
Journal:  Am J Pathol       Date:  2007-02       Impact factor: 4.307

Review 7.  Future perspectives: cancer metastases.

Authors:  Stanley P Leong; Jonathan S Zager
Journal:  Clin Exp Metastasis       Date:  2018-07-23       Impact factor: 5.150

8.  Final trial report of sentinel-node biopsy versus nodal observation in melanoma.

Authors:  Donald L Morton; John F Thompson; Alistair J Cochran; Nicola Mozzillo; Omgo E Nieweg; Daniel F Roses; Harold J Hoekstra; Constantine P Karakousis; Christopher A Puleo; Brendon J Coventry; Mohammed Kashani-Sabet; B Mark Smithers; Eberhard Paul; William G Kraybill; J Gregory McKinnon; He-Jing Wang; Robert Elashoff; Mark B Faries
Journal:  N Engl J Med       Date:  2014-02-13       Impact factor: 91.245

9.  Carbon coated superparamagnetic iron oxide nanoparticles for sentinel lymph nodes mapping.

Authors:  Yi-Xiang J Wang; Da-Wei Wang; Xiao-Ming Zhu; Feng Zhao; Ken Cf Leung
Journal:  Quant Imaging Med Surg       Date:  2012-03

Review 10.  Significance of sentinel lymph node biopsy in malignant melanoma: overview of international data.

Authors:  Yoichi Moroi
Journal:  Int J Clin Oncol       Date:  2009-12-05       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.